NTRBWNutriband Inc. Warrant
0.5000USD+25.06%Mkt Cap: —P/E: —3d ago
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. Its lead product is AVERSA Fentanyl, an abuse deterrent fentanyl patch for the treatment of chronic pain. The company also …
Industry Peers
Biotechnology$138.82BUSDP/E 31.9
$85.87BUSDP/E 20.5
$61.34BUSDP/E 39.8
$65.05BUSDP/E 39.6
$57.94BUSD
$45.95BUSDP/E 19.6
$44.89BUSD
$42.36BUSDP/E 67.2
$35.43BUSDP/E 32.6
$31.61BUSDP/E 41.2
$29.28BUSD
$27.47BUSD
$26.22BUSD
$25.91BUSDP/E 16.2
$20.86BUSDP/E 26.3
$19.26BUSDP/E 26.6
$16.61BUSDP/E 19.6
$16.51BUSDP/E 17.4
$15.93BUSD
$13.40BUSDP/E 17.0
Key Statistics
Company
Market Cap—
Enterprise Value—
Revenue (TTM)1.80M $
Gross Profit566.31K $
Net Income (TTM)-8.23M $
Revenue/Share0.1510 USD
Last Price0.5000 USD
Fiscal Year End—
MR Quarter—
Employees—
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B0.81
EPS (TTM)-0.51
EPS (Forward)—
52W Range
0.35444% of range4.500
52W High4.500 USD
52W Low0.3544 USD
Profitability
Gross Margin27.81%
Oper. Margin-289.42%
EBITDA Margin0.00%
Profit Margin-404.08%
ROE-123.21%
ROA-109.03%
Growth
Revenue Growth-35.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF-5.13M $
CapEx (TTM)5.32K $
FCF Margin-95.65%
FCF Yield—
Net Debt-3.77M $
Net Debt/EBITDA0.47
Balance Sheet
Debt/Equity0.04
Current Ratio5.26
Quick Ratio4.82
Book Value/Sh0.4930 USD
Cash/Share0.3300 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.—
Float5.28M
Insiders—
Institutions—
Technical
SMA 500.6576 (-24.0%)
SMA 2001.204 (-58.5%)
Beta1.97
S&P 52W Chg18.16%
Avg Vol (30d)2.43K
Avg Vol (10d)50
Technical Indicators
RSI (14)25.6
MACD-0.1199
MACD Signal-0.0335
MACD Hist.-0.0865
BB Upper1.861 USD
BB Middle1.226 USD
BB Lower0.5907 USD
BB Width103.63%
ATR (14)0.1400 USD
Vol Ratio (20d)89.09x